Compare CSX Corporation (CSX) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Johnson & Johnson — how do they compare? CSX Corporation trades at $47.26 (market cap $87.70B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 7× CSX Corporation's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Johnson & Johnson for 129 Days on average.
| CSX | JNJ | |
|---|---|---|
Market Cap | $87.70B | $618.09B |
Volume | 6,980,781 | 6,050,983 |
Sector | Industrials | Health |
52-Week High | $53.21 | $278.43 |
52-Week Low | $33.68 | $186.00 |
Typical Hold Time | 55 Days | 129 Days |
Enterprise Value | $105.66B | $646.37B |
Dividend Yield | 1.18% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.34, up 1.13% today, with a bullish technical signal and strong institutional interest. Recent earnings show a beat in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue has declined from $14.9B in 2022 to $14.1B in 2025, with net income falling to $2.89B. The company maintains solid profitability with a 22.21% net margin and 24.37% ROE, but valuation ratios like P/E of 27.52 and P/S of 6.08 appear elevated. A dividend of $0.14 is scheduled for payment in September 2026.
The outlook for CSX is cautiously optimistic, supported by analyst consensus with a $51 price target and 58.69% buy ratings. Key opportunities include pricing power in freight rail and expected earnings recovery in 2026. Risks involve revenue declines, high debt levels, and sensitivity to economic cycles. The stock's current technical strength and institutional accumulation suggest potential upside if operational trends improve.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
